
Merck
Impact of Synthia on GSK Chemical Development
The webinar focused on the advancements in SYNTHIA™ Retrosynthesis Software and its impact on chemical development at GlaxoSmithKline (GSK), presented by John Lim from GSK. John highlighted how SYNTHIA™ has become an integral tool in GSK's chemical development process, aiding in route selection and synthesis planning. The software's ability to suggest diverse, high-quality synthetic routes has enhanced GSK's confidence in their chosen pathways...
Register for webinar


John Lim, Dr. Ewa Gajewska
Impact of Synthia on GSK Chemical Development